Simple DNA test could shield gout patients from deadly skin side effects
NCT ID NCT07369622
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a genetic test can prevent rare but severe skin reactions caused by the common gout drug allopurinol. About 228 Vietnamese adults with gout will either get the test before treatment or receive standard care. Those with a high-risk gene will take a different drug (febuxostat) instead. The goal is to see if this approach is safer and cost-effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- allopurinol and febuxostat
- What this could lead to
- If successful, this approach could prevent life-threatening skin reactions in people starting gout treatment, making therapy safer for those with a specific genetic risk.
- What could go wrong
- This is a small, single-site study in Vietnam, so results may not apply to other populations. The genetic test is only for one risk factor, and other rare reactions could still occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT AND HYPERURICEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody injection could stop gout flares while lowering uric acid
- Do kidney donors face higher gout risk later in life?
- New gout pill BR2251 enters Mid-Stage trial
- New gel injection aims to tame gout flare pain in days
- Digital health program could transform diabetes care for seniors with multiple illnesses
- Pedal vs pound: study tests if cycling beats jogging for gout relief